Cellectar Biosciences Stock Buy Hold or Sell Recommendation
| CLRB Stock | USD 4.72 0.12 2.48% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Cellectar Biosciences is 'Cautious Hold'. Macroaxis provides Cellectar Biosciences buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CLRB positions.
Check out Cellectar Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide. In addition, we conduct extensive research on individual companies such as Cellectar and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Cellectar Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Cellectar | Build AI portfolio with Cellectar Stock |
Execute Cellectar Biosciences Buy or Sell Advice
The Cellectar recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cellectar Biosciences. Macroaxis does not own or have any residual interests in Cellectar Biosciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cellectar Biosciences' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Cellectar Biosciences Trading Alerts and Improvement Suggestions
| Cellectar Biosciences generated a negative expected return over the last 90 days | |
| Cellectar Biosciences has high historical volatility and very poor performance | |
| Cellectar Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (44.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cellectar Biosciences currently holds about 24.81 M in cash with (47.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.06. | |
| Cellectar Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: How does CLRBs Q3 earnings surprise impact short-term trades - AInvest |
Cellectar Biosciences Returns Distribution Density
The distribution of Cellectar Biosciences' historical returns is an attempt to chart the uncertainty of Cellectar Biosciences' future price movements. The chart of the probability distribution of Cellectar Biosciences daily returns describes the distribution of returns around its average expected value. We use Cellectar Biosciences price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cellectar Biosciences returns is essential to provide solid investment advice for Cellectar Biosciences.
| Mean Return | -0.39 | Value At Risk | -13.52 | Potential Upside | 7.50 | Standard Deviation | 11.14 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cellectar Biosciences historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Cellectar Stock Institutional Investors
| Shares | Two Sigma Investments Llc | 2025-03-31 | 83.1 K | Northern Trust Corp | 2025-03-31 | 78 K | Hrt Financial Llc | 2025-03-31 | 46.2 K | Adar1 Capital Management Llc | 2025-03-31 | 40.2 K | Nordwand Advisors Llc | 2025-03-31 | 20 K | Justinvest Llc | 2025-03-31 | 17.6 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 15.3 K | Oppenheimer & Co Inc | 2025-03-31 | 12.5 K | Commonwealth Equity Services Inc | 2025-03-31 | 12.1 K | Vanguard Group Inc | 2025-03-31 | 1.7 M | Ubs Group Ag | 2025-03-31 | 920.4 K |
Cellectar Biosciences Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Free Cash Flow | (14.0M) | (22.7M) | (25.4M) | (33.2M) | (47.7M) | (45.3M) | |
| Depreciation | 141.5K | 149.9K | 148.4K | 192.4K | 291.7K | 282.5K | |
| Other Non Cash Items | 66.5K | 77.7K | 93.8K | 38.6M | (5.8M) | (5.5M) | |
| Capital Expenditures | 62.4K | 141.4K | 226.0K | 864.0K | 104.2K | 147.1K | |
| Net Income | (15.1M) | (24.1M) | (28.6M) | (38.0M) | (44.6M) | (42.4M) | |
| End Period Cash Flow | 57.2M | 35.7M | 19.9M | 9.6M | 23.3M | 13.3M | |
| Change In Cash | 46.6M | (21.5M) | (15.8M) | (10.3M) | 13.7M | 14.4M | |
| Change To Netincome | 823.8K | 282.3K | 1.2M | 1.5M | 1.8M | 1.9M | |
| Investments | (62.4K) | (141.4K) | (226.0K) | (715.1K) | (104.2K) | (109.4K) |
Cellectar Biosciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cellectar Biosciences or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cellectar Biosciences' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cellectar stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.54 | |
β | Beta against Dow Jones | 1.35 | |
σ | Overall volatility | 11.19 | |
Ir | Information ratio | -0.04 |
Cellectar Biosciences Volatility Alert
Cellectar Biosciences is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cellectar Biosciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cellectar Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Cellectar Biosciences Fundamentals Vs Peers
Comparing Cellectar Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cellectar Biosciences' direct or indirect competition across all of the common fundamentals between Cellectar Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cellectar Biosciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cellectar Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cellectar Biosciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cellectar Biosciences to competition |
| Fundamentals | Cellectar Biosciences | Peer Average |
| Return On Equity | -2.09 | -0.31 |
| Return On Asset | -0.98 | -0.14 |
| Current Valuation | 660.89 K | 16.62 B |
| Shares Outstanding | 2.86 M | 571.82 M |
| Shares Owned By Insiders | 2.15 % | 10.09 % |
| Shares Owned By Institutions | 6.50 % | 39.21 % |
| Number Of Shares Shorted | 66.9 K | 4.71 M |
| Price To Earning | (1.35) X | 28.72 X |
| Price To Book | 1.75 X | 9.51 X |
| EBITDA | (44.22 M) | 3.9 B |
| Net Income | (44.58 M) | 570.98 M |
| Cash And Equivalents | 24.81 M | 2.7 B |
| Cash Per Share | 4.06 X | 5.01 X |
| Total Debt | 494 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 4.51 X | 2.16 X |
| Book Value Per Share | 5.03 X | 1.93 K |
| Cash Flow From Operations | (47.58 M) | 971.22 M |
| Short Ratio | 0.40 X | 4.00 X |
| Earnings Per Share | (18.90) X | 3.12 X |
| Target Price | 120.0 | |
| Number Of Employees | 11 | 18.84 K |
| Beta | 0.51 | -0.15 |
| Market Capitalization | 13.49 M | 19.03 B |
| Total Asset | 25.47 M | 29.47 B |
| Retained Earnings | (247.34 M) | 9.33 B |
| Working Capital | 14.86 M | 1.48 B |
| Current Asset | 8.14 M | 9.34 B |
| Current Liabilities | 1.39 M | 7.9 B |
| Net Asset | 25.47 M |
Note: Acquisition by Hill Stephen A of 50000 shares of Cellectar Biosciences at 1.28 subject to Rule 16b-3 [view details]
Cellectar Biosciences Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cellectar . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Cellectar Biosciences Buy or Sell Advice
When is the right time to buy or sell Cellectar Biosciences? Buying financial instruments such as Cellectar Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Cellectar Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run SRI Sustainable Growth Thematic Idea Now
SRI Sustainable Growth
Socially responsible investments that include companies making a positive, sustainable or social impact and exclude those making a negative impact. The SRI Sustainable Growth theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SRI Sustainable Growth Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Cellectar Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.